Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab
Abstract Digital health technology (DHT) tools for Parkinson’s disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were ra...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | npj Digital Medicine |
| Online Access: | https://doi.org/10.1038/s41746-025-01572-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849685811108249600 |
|---|---|
| author | Kirsten I. Taylor Florian Lipsmeier Marzia A. Scelsi Ekaterina Volkova-Volkmar Daria Rukina Werner Popp Stefan Lambrecht Judith Anzures-Cabrera David Summers Markus Abt Annabelle Monnet Timothy Kilchenmann Jens Schjodt-Eriksen Laurent Essioux Thomas Kustermann Wagner Zago Hanno Svoboda Tania Nikolcheva Ronald B. Postuma Gennaro Pagano Michael Lindemann PASADENA Investigators Prasinezumab Study Group |
| author_facet | Kirsten I. Taylor Florian Lipsmeier Marzia A. Scelsi Ekaterina Volkova-Volkmar Daria Rukina Werner Popp Stefan Lambrecht Judith Anzures-Cabrera David Summers Markus Abt Annabelle Monnet Timothy Kilchenmann Jens Schjodt-Eriksen Laurent Essioux Thomas Kustermann Wagner Zago Hanno Svoboda Tania Nikolcheva Ronald B. Postuma Gennaro Pagano Michael Lindemann PASADENA Investigators Prasinezumab Study Group |
| author_sort | Kirsten I. Taylor |
| collection | DOAJ |
| description | Abstract Digital health technology (DHT) tools for Parkinson’s disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were randomized to placebo, 1500 mg, or 4500 mg prasinezumab for 52 weeks; placebo participants were re-randomized to prasinezumab for the ensuing 52 weeks. Patients performed daily smartphone motor “active tests”, and were passively monitored by smartphone/smartwatch throughout the day over 2 y. Change from baseline analyses censored data at dopaminergic treatment start. Bilateral speeded tapping variability and hand-turning, U-turn speed, passively monitored hand movement power, and summary Simple Sum scores progressed numerically less in prasinezumab-treated vs placebo at week 52. All findings except hand-turning persisted at week 104. DHT sensor-based outcome measures may contribute to quantifying disease progression in clinical research of early-stage, dopaminergic treatment-naïve PD. Clinical Trial Registry Name: ClinicalTrials.gov; Clinical Trial Registry ID: NCT03100149; registered 2017-03-29. |
| format | Article |
| id | doaj-art-3db7afce2e4243669f991db2ec2171bb |
| institution | DOAJ |
| issn | 2398-6352 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Digital Medicine |
| spelling | doaj-art-3db7afce2e4243669f991db2ec2171bb2025-08-20T03:22:57ZengNature Portfolionpj Digital Medicine2398-63522025-06-018111210.1038/s41746-025-01572-8Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumabKirsten I. Taylor0Florian Lipsmeier1Marzia A. Scelsi2Ekaterina Volkova-Volkmar3Daria Rukina4Werner Popp5Stefan Lambrecht6Judith Anzures-Cabrera7David Summers8Markus Abt9Annabelle Monnet10Timothy Kilchenmann11Jens Schjodt-Eriksen12Laurent Essioux13Thomas Kustermann14Wagner Zago15Hanno Svoboda16Tania Nikolcheva17Ronald B. Postuma18Gennaro Pagano19Michael Lindemann20PASADENA InvestigatorsPrasinezumab Study GroupRoche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Product Development Data Sciences, Roche Products LtdRoche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Product Development Data Sciences, Roche Products LtdProduct Development Data Sciences, Roche Products LtdProduct Development Data Sciences, Hoffmann-La Roche Ltd.Product Development Data Sciences, Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Product Development Data Sciences, Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Prothena Biosciences Inc, South San FranciscoRoche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Innovation Center Basel, and Product Development Neuroscience, F. Hoffmann-La Roche Ltd.Department of Neurology, McGill University, Montreal General HospitalRoche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.Abstract Digital health technology (DHT) tools for Parkinson’s disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were randomized to placebo, 1500 mg, or 4500 mg prasinezumab for 52 weeks; placebo participants were re-randomized to prasinezumab for the ensuing 52 weeks. Patients performed daily smartphone motor “active tests”, and were passively monitored by smartphone/smartwatch throughout the day over 2 y. Change from baseline analyses censored data at dopaminergic treatment start. Bilateral speeded tapping variability and hand-turning, U-turn speed, passively monitored hand movement power, and summary Simple Sum scores progressed numerically less in prasinezumab-treated vs placebo at week 52. All findings except hand-turning persisted at week 104. DHT sensor-based outcome measures may contribute to quantifying disease progression in clinical research of early-stage, dopaminergic treatment-naïve PD. Clinical Trial Registry Name: ClinicalTrials.gov; Clinical Trial Registry ID: NCT03100149; registered 2017-03-29.https://doi.org/10.1038/s41746-025-01572-8 |
| spellingShingle | Kirsten I. Taylor Florian Lipsmeier Marzia A. Scelsi Ekaterina Volkova-Volkmar Daria Rukina Werner Popp Stefan Lambrecht Judith Anzures-Cabrera David Summers Markus Abt Annabelle Monnet Timothy Kilchenmann Jens Schjodt-Eriksen Laurent Essioux Thomas Kustermann Wagner Zago Hanno Svoboda Tania Nikolcheva Ronald B. Postuma Gennaro Pagano Michael Lindemann PASADENA Investigators Prasinezumab Study Group Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab npj Digital Medicine |
| title | Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab |
| title_full | Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab |
| title_fullStr | Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab |
| title_full_unstemmed | Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab |
| title_short | Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab |
| title_sort | exploratory digital outcome measures of motor sign progression in parkinson s disease patients treated with prasinezumab |
| url | https://doi.org/10.1038/s41746-025-01572-8 |
| work_keys_str_mv | AT kirstenitaylor exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT florianlipsmeier exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT marziaascelsi exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT ekaterinavolkovavolkmar exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT dariarukina exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT wernerpopp exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT stefanlambrecht exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT judithanzurescabrera exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT davidsummers exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT markusabt exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT annabellemonnet exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT timothykilchenmann exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT jensschjodteriksen exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT laurentessioux exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT thomaskustermann exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT wagnerzago exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT hannosvoboda exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT tanianikolcheva exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT ronaldbpostuma exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT gennaropagano exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT michaellindemann exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT pasadenainvestigators exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab AT prasinezumabstudygroup exploratorydigitaloutcomemeasuresofmotorsignprogressioninparkinsonsdiseasepatientstreatedwithprasinezumab |